Clinical Trial Update: Study of the Safety, Pharmacodynamics and Efficacy of ANB-002 in Patients With Hemophilia B (SAFRAN) [Phase 1, Phase 2]

View source ↗

Summary

Biocad's ANB-002 is being studied in the SAFRAN Phase 1/2 trial for Hemophilia B and is currently recruiting to evaluate safety, pharmacodynamics, and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• ANB-002

Snippet

Sponsor: Biocad | Conditions: Hemophilia B | Phase 1, Phase 2 | Status: RECRUITING